ReviewNaunyn-Schmiedeberg's archives of pharmacology2020
A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of Interferon-β in Moderate-to-Severe Hospitalised Cases of COVID-19: A Systematic Review and Meta-analysis.Clinical drug investigation · 2021Pooled it
- Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies.Naunyn-Schmiedeberg's archives of pharmacology · 2021Pooled it
- Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial.Journal of medical virology · 2022Trial
- In silico screening and experimental validation identify riboflavin as an RNA-targeted antiviral against SARS-CoV-2.Scientific reports · 2025Article
- Structure-based approaches against COVID-19.Journal of the Chinese Medical Association : JCMA · 2024Review
- Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLScientific reports · 2023Article
- DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action.Viruses · 2023Article
- A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants.Archives of microbiology · 2023Review
- Article
- Acetylsalicylic Acid-Primus Inter Pares in Pharmacology.Molecules (Basel, Switzerland) · 2022Review
- Repositioning Drugs for Rare Diseases Based on Biological Features and Computational Approaches.Healthcare (Basel, Switzerland) · 2022Article
- Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Cryo-EM structures of human bradykinin receptor-GNature communications · 2022Article
- Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation.Briefings in bioinformatics · 2022Article
- SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review.International journal of biological macromolecules · 2021Review
- Virtual screening of peptides with high affinity for SARS-CoV-2 main protease.Computers in biology and medicine · 2021Article
- Review of registered clinical trials for the treatment of COVID-19.Drug development research · 2021Review
- A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study.Life science alliance · 2021Article
- Pathogenetic profiling of COVID-19 and SARS-like viruses.Briefings in bioinformatics · 2021Article
- Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the reason for this ongoing pandemic infection diseases termed coronavirus disease 2019 (COVID-19) that has emerged since early December 2019 in Wuhan City, Hubei Province, China. In this century, it is the worst threat to international health and the economy. After 4 months of COVID-19 outbreak, there is no certain and approved medicine against it. In this public health emergency, it makes sense to investigate the possible effects of old drugs and find drug repositioning that is efficient, economical, and riskless process. Old drugs that may be effective are from different pharmacological categories, antimalarials, anthelmintics, anti-protozoal, anti-HIVs, anti-influenza, anti-hepacivirus, antineoplastics, neutralizing antibodies, immunoglobulins, and interferons. In vitro, in vivo, or preliminary trials of these drugs in the treatment of COVID-19 have been encouraging, leading to new research projects and trials to find the best drug/s. In this review, we discuss the possible mechanisms of these drugs against COVID-19. Also, it should be mentioned that in this manuscript, we discuss preliminary rationales; however, clinical trial evidence is needed to prove them. COVID-19 therapy must be based on expert clinical experience and published literature and guidelines from major health organizations. Moreover, herein, we describe current evidence that may be changed in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.